Premium
Treatment of lower torso stages I and Ii Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine, and prednisone
Author(s) -
Givens Stanley S.,
Fuller Lillian M.,
Hagemeister Fredrick B.,
Gehan Edmund A.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900701)66:1<69::aid-cncr2820660114>3.0.co;2-r
Subject(s) - medicine , procarbazine , prednisone , vincristine , radiation therapy , laparotomy , surgery , chemotherapy , cyclophosphamide
From 1956 to 1987, 60 patients with either lymphangiogram‐staged or laparotomy‐staged I‐II lower torso presentations of Hodgkin's disease were treated with radiation with or without Mustargen (mechlorethamine), vincristine, procarbazine, and prednisone (MOPP). in 22 with inguinal/femoral or pelvic disease and 24 with abdominal disease, treatment consisted of radiation only. Fourteen other patients with abdominal disease received MOPP chemotherapy before radiotherapy. in 11, the chemotherapy was limited to two cycles. At 10 years, the determinate survival and freedom from progression rates for all patients were 82% and 72%, respectively. for patients with inguinal/femoral or pelvic disease who were treated with radiation only, the corresponding rates were 90% and 86%. for patients with abdominal disease who received radiation only, the determinate survival and the freedom from progression rates were only 66% and 50%, respectively. However, corresponding results for 14 patients with abdominal disease who were treated with MOPP and radiation were 100% and 92% ( P = 0.033 and P = 0.009, respectively).